836 related articles for article (PubMed ID: 9449701)
21. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
23. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
25. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
26. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects.
Okajima K; Koga S; Kaji M; Inoue M; Nakagaki T; Funatsu A; Okabe H; Takatsuki K; Aoki N
Thromb Haemost; 1990 Feb; 63(1):48-53. PubMed ID: 2140205
[TBL] [Abstract][Full Text] [Related]
27. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
28. Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
He HY; Wang C; Pang BS
Chin Med J (Engl); 2008 Dec; 121(24):2561-5. PubMed ID: 19187596
[TBL] [Abstract][Full Text] [Related]
29. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
Pizzo SV; Schwartz ML; Hill RL; McKee PA
J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
[TBL] [Abstract][Full Text] [Related]
31. [Activated protein C, coagulation, inflammation, and treatment of severe sepsis].
van Deventer SJ; Pajkrt D
Ned Tijdschr Geneeskd; 2001 Mar; 145(13):613-6. PubMed ID: 11305209
[TBL] [Abstract][Full Text] [Related]
32. The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies.
Ieko M; Sawada KI; Koike T; Notoya A; Mukai M; Kohno M; Wada N; Itoh T; Yoshioka N
Semin Thromb Hemost; 1999; 25(5):503-7. PubMed ID: 10625210
[TBL] [Abstract][Full Text] [Related]
33. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
34. The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin.
Kumar R; Béguin S; Hemker HC
Thromb Haemost; 1994 Nov; 72(5):713-21. PubMed ID: 7900079
[TBL] [Abstract][Full Text] [Related]
35. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
36. Plasma factor V activation is prevented by activated protein C in the presence of phospholipid vesicles, not platelets.
Solymoss S; Nguyen KT
Thromb Haemost; 1993 Feb; 69(2):124-9. PubMed ID: 8456424
[TBL] [Abstract][Full Text] [Related]
37. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin.
Abrahamsson T; Nerme V; Strömqvist M; Akerblom B; Legnehed A; Pettersson K; Westin Eriksson A
Thromb Haemost; 1996 Jan; 75(1):118-26. PubMed ID: 8713790
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats.
Malm K; Arnljots B; Persson IM; Dahlbäck B
Thromb Res; 2007; 120(4):531-9. PubMed ID: 17169412
[TBL] [Abstract][Full Text] [Related]
39. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Wygrecka M; Jablonska E; Guenther A; Preissner KT; Markart P
Thromb Haemost; 2008 Mar; 99(3):494-501. PubMed ID: 18327397
[TBL] [Abstract][Full Text] [Related]
40. [Protein C: mechanisms of activation and anticoagulant effect].
Kogan AE; Strukova SM
Biokhimiia; 1993 Jun; 58(6):827-44. PubMed ID: 8364108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
